Adenocarcinoma of the rectum and anus in a patient with Crohn's disease treated with infliximab.
In the present paper, we report the case of a patient with long-standing Crohn s disease and multiple complications that, after receiving treatment with infliximab, was diagnosed with an adenocarcinoma of the rectum and anus that required radical surgery, later presenting multiple metastases. In the discussion, characteristics and major risk factors for colorectal cancer in patients with inflammatory bowel disease will be largely reviewed, and current studies will be analyzed in connection with the appearance of neoplasms in patients being treated with biologics.
Egea-Valenzuela
J
J
Department of Digestive Diseases, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. juanegeavalenzuela@gmail.com
Belchí-Segura
E
E
Essouri
N
N
Sánchez-Torres
A
A
Carballo-Alvarez
F
F
D000230:Adenocarcinoma / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000139:chemically induced*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab